2020年4月9日 · Chimeric antigen receptor T-cell (CAR-T) therapy yields durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Cytokine release syndrome (CRS) is a CAR-T therapy–related adverse event.

2023年7月1日 · Cytokine release syndrome (CRS), observed in 72.1% of patients treated with teclistamab in the MajesTEC-1 study, was mostly grade 1 or 2 and manageable, without requiring treatment discontinuation. Most CRS occurred during the step-up schedule, requiring vigilance during treatment initiation.

Two major toxicities arising from CAR T cells were not revealed in early mouse models but were eventually observed in clinical trials — cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS; often referred to as neurotoxicity).

CRS can present with a variety of symptoms ranging from mild, flu-like symptoms to severe life-threatening manifestations of the overshooting inflammatory response (Fig. 1). Mild symptoms of CRS include fever, fatigue, headache, rash, arthralgia, and myalgia.

2023年5月18日 · We discuss our approach to managing refractory toxicities that persist or progress beyond initial tocilizumab or corticosteroid administration, delineate risk factors for severe toxicities, highlight the emerging use of anakinra, and review mitigation strategies and supportive care measures to improve outcomes in patients who develop these refra...

CRS is a systemic inflammatory response caused by the release of inflammatory cytokines, such as IL-6, interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), IL-2, and IL-10, by large number of activated lymphocytes (B cells, T cells, and/or natural killer cells) and/or myeloid cells (macrophages, dendritic cells, and monocytes) which can ...

2018年11月10日 · Here we report the consensus recommendations of that group and propose new definitions and grading for CRS and neurotoxicity that are objective, easy to apply, and ultimately more accurately categorize the severity of these toxicities.

2019年1月1日 · Le syndrome de relargage des cytokines (CRS) a été décrit avec l’utilisation de différentes thérapeutiques et surtout des immunothérapies adoptives telles que les cellules CAR-T (CAR-T). Le CRS est la complication la plus fréquente …

2014年7月10日 · Cytokine release syndrome (CRS) is a potentially life-threatening toxicity that has been observed following administration of natural and bispecific antibodies and, more recently, following adoptive T-cell therapies for cancer.

Il existe quatre types de statuts : 1. Entité exemptée. C’est l’option à choisir si votre société correspond à l’une des définitions suivantes : une entité publique, organisation internationale, banque centrale, fonds de pension exempté (en vertu d’accords intergouvernementaux). 2. Institution financière.